Skip to main content
ProBiotix Health Plc logo

ProBiotix Health Plc — Investor Relations & Filings

Ticker · PBX ISIN · GB00BLNBFR86 LEI · 98450048683CF0388C30 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 66 across all filing types
Latest filing 2025-10-13 Earnings Release
Country GB United Kingdom
Listing Aquis Stock Exchange PBX

About ProBiotix Health Plc

https://www.probiotixhealth.com/

ProBiotix Health Plc is a life sciences company that develops and supplies scientifically validated, probiotic-based microbiome solutions. The company specializes in formulations for cardiometabolic health, targeting conditions related to cholesterol, blood pressure, and vascular health, as well as healthy aging. Its core technology is LPLDL®, a patented and trademarked Lactobacillus plantarum strain demonstrated in human clinical trials to be effective in managing key cardiometabolic markers. ProBiotix Health offers its technology as both a raw ingredient and in finished product formulations, such as the YourBiotix and CholBiome® lines, for the global dietary supplement market. The company's approach is rooted in extensive research and development, conducted in collaboration with universities and scientific advisors to ensure product efficacy and safety.

Recent filings

Filing Released Lang Actions
Q3 2025 Trading Update and Grant of Options
Earnings Release Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from ProBiotix Health plc. It provides a Q3 2025 trading update, which includes key financial highlights (sales, gross profit, cash balance) and an announcement regarding the grant of share options to senior management. While it contains financial data, it is a short, high-level summary announcement rather than a full quarterly report or a formal management report. Given the primary purpose is to announce trading performance and management changes via a regulatory news service, it fits the 'Earnings Release' (ER) category for the trading update portion, but since it is a standard RNS announcement covering multiple topics, 'RNS' is the most accurate classification for this type of regulatory disclosure. 9M 2025
2025-10-13 English
Unaudited Interim Results to 30 June 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Interim Results to 30 June 2025' for ProBiotix Health plc. It contains comprehensive financial statements, including a Consolidated Statement of Comprehensive Income, and detailed management commentary on business performance, operational highlights, and strategic outlook for the six-month period. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-08 English
Trading Update and Notice of Results
Earnings Release Classification · 100% confidence The document is titled "Trading Update and Notice of Results" and provides key financial highlights (revenue, profit, EBITDA loss) for the six months ended 30 June 2025. This content strongly suggests an announcement of interim financial performance. However, the document explicitly states: "ProBiotix will release its interim results for the six months to 30 June 2025 on Monday, 8 September 2025." Since this document is an update *announcing* the upcoming release of the full interim results, it functions as an Earnings Release (ER) or a preliminary announcement of results, rather than the comprehensive Interim Report (IR) itself. Given the focus on key financial highlights preceding the full results release, 'ER' (Earnings Release) is the most appropriate classification, as it precedes the comprehensive 'IR'. The document is also formatted as an RNS announcement. H1 2025
2025-07-15 English
Result of AGM and Notice of Trading Update
AGM Information Classification · 99% confidence The document explicitly states 'Result of AGM and Notice of Trading Update' and confirms that 'at the AGM held earlier today, all resolutions were duly passed.' This directly relates to the outcome of an Annual General Meeting. Although it mentions the AGM result, the primary function of this short announcement is to communicate the outcome and provide a notice about a future trading update. Since the document confirms the passing of resolutions at the AGM, the most specific code is AGM-R (AGM Information). It is not a DVA (Declaration of Voting Results) because it only states resolutions passed, not the detailed voting breakdown, and it is not an ER (Earnings Release) or IR (Interim Report). Given the context of reporting the AGM outcome, AGM-R is the best fit.
2025-06-27 English
PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a share acquisition by a Person Discharging Managerial Responsibilities (PDMR). It explicitly includes the standard regulatory disclosure table for transactions by PDMRs, detailing the name, position, instrument type, volume, and price. This falls directly under the category of Director's Dealing (DIRS).
2025-06-09 English
Notice of Annual General Meeting - Clarification
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via RNS regarding a clarification of a resolution in a previously published Notice of Annual General Meeting. It does not contain the full meeting materials or the meeting itself, but rather serves as a corrective notice related to the AGM process. Given it is a regulatory announcement regarding meeting materials, it fits best under the RNS category as a general regulatory filing.
2025-06-05 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.